YOKOGAWA/SENSIRE
6.6.2019 08:02:06 CEST | Business Wire | Press release
Yokogawa Electric Corporation (TOKYO:6841) and Finland-based Sensire Ltd. announce that they have reached an agreement for Yokogawa to take a €6 million stake in Sensire and to begin collaborating in the cold chain monitoring field. Through this initiative, both companies aim to develop and provide new services that combine Yokogawa’s Industrial Internet of Things (IIoT) architecture, subscription-based IIoT services being developed by its amnimo Inc. subsidiary, and Sensire’s cold chain temperature monitoring solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190605005285/en/
Demand for solutions that facilitate the temperature-controlled transportation of perishable items from the point of origin to the point of consumption is on the rise, and this need is particularly acute with pharmaceutical and food products that require strict temperature control.
Sensire Ltd. offers a full range of specialized temperature monitoring solutions mainly for the cold chain. Sensire’s compact and power efficient temperature sensors collect and transmit temperature data to the cloud for access from PCs and mobile devices. Supporting a range of wireless communication protocols suitable for land, sea, and air transport applications, Sensire’s solutions ensure access to continuous real-time monitoring data that delivers vital quality and compliance information when and where it is needed.
Yokogawa is developing a cloud-based IIoT architecture in collaboration with Microsoft Corporation of the United States, and based on this is starting to provide solutions for the remote monitoring of physical quantities. In addition, Yokogawa’s amnimo Inc. business unit is developing IIoT services that use this architecture to provide access to data from not only manufacturing plants but also many other types of facilities and situations, with the aim of delivering subscription-based Measurement as a Service (MaaS).
Having taken a 35.2% stake in Sensire, Yokogawa is now this company’s largest shareholder. Utilizing Yokogawa’s know-how and global network, the two companies will work together to develop new temperature monitoring solutions for the cold chain and other logistics services, and expand this business.
Tsuyoshi Abe, a Yokogawa senior vice president and head of the company’s Marketing Headquarters, commented, “Under its Transformation 2020 mid-term business plan, Yokogawa is now exploring new business models such as recurring revenue while also aiming to expand its business in the pharmaceutical and food fields. I am convinced that Sensire’s solutions will accelerate these efforts, and I trust that we will be able to deliver new value to applications where precise temperature control is critical by combining the technologies of both companies.”
JP Asikainen, founder and CEO of Sensire, added, “I believe that this collaboration with Yokogawa will provide us an opportunity to expand the business globally and ensure the transition to the next-generation of cloud architecture. We look forward to making the latest and best cold chain solutions available to customers in a broader range of industries and applications.”
Related links
amnimo
Inc
.
About Yokogawa
Founded in 1915, Yokogawa engages in
broad-ranging activities in the areas of measurement, control, and
information. The industrial automation business provides vital products,
services, and solutions to a diverse range of process industries
including oil, chemicals, natural gas, power, iron and steel, and pulp
and paper. With the life innovation business, the company aims to
radically improve productivity across the pharmaceutical and food
industry value chains. The test & measurement, aviation, and other
businesses continue to provide essential instruments and equipment with
industry-leading precision and reliability. Yokogawa co-innovates with
its customers through a global network of 113 companies spanning 60
countries, generating US$3.6 billion in sales in FY2018. For more
information, please visit www.yokogawa.com
.
About Sensire
Sensire Ltd., founded in 2007 by CEO JP
Asikainen, offers comprehensive wireless and automatic real-time
monitoring products that serve the globally vital climate-controlled
chain. The IoT tech company’s solutions help deliver better safety and
quality in various cold chain operations from food industry applications
to pharmaceutical logistics, as well as in many climate-sensitive
healthcare premises. Sensire is committed to being the leading innovator
in cold chain IoT technology in order to offer best-in-class products
and services to its customers. Headquartered in Joensuu, Finland, the
company turnover in FY2018 was EUR 1.5 million. For more information,
visit www.sensire.com
The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation, Sensire Ltd., or their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190605005285/en/
Contact:
Yokogawa Electric Corporation Philip Lewis Public Relations Manager Email: Yokogawa-pr@cs.jp.yokogawa.com 2-9-32 Nakacho Musashino-shi Tokyo Japan 180-8750 Tel: +81 422-52-5530
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 14:05:00 CEST | Press release
Significant unmet need remains for 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burdenEnpatoran, an oral TLR7/8 inhibitor, is designed for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standardsELOWEN is a global Phase 3 program evaluating enpatoran’s impact on both skin and systemic symptoms in patients with lupus and potential links between skin and systemic disease activity Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People
Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 14:00:00 CEST | Press release
Celebrating the ecommerce leaders from Michael Kors and Gymshark shaping the future of fraud prevention and risk management Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are:Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of
The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 14:00:00 CEST | Press release
The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
